News

Zydus Life in focus after launch of India’s first affordable OPEP device for asthma, bronchiectasisZydus Lifesciences launched PEPAIR™, India’s first affordable OPEP device for COPD, asthma and bronchiectasis, priced at ₹990, in partnership with AeroDel Technology Innovations Pvt. Ltd.By Gareema Bangad  February 17, 2026, 12:01:35 PM IST (Published)3 Min Read(Photo Credit : CNBC-TV18 Library )Zydus Lifesciences Limited has launched PEPAIR™, India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) device, aimed at improving respiratory health for patients suffering from chronic lung conditions, the company announced on Tuesday, February 17.

In an exchange filing, Zydus Life said the drug-free, handheld device is designed to support mucus clearance and improve breathing in patients with COPD, asthma and bronchiectasis. PEPAIR™ has been positioned as an affordable airway clearance solution, priced at ₹990 per unit.

The company said more than 90 lakh patients in India suffer from these chronic respiratory conditions, many of whom require daily airway clearance therapy due to persistent mucus build-up.

Also read: TVS Supply Chain shares rallies 6% after MoU with Italy’s ALA to tap $28 billion aerospace market

PEPAIR™ has been launched in partnership with AeroDel Technology Innovations Pvt. Ltd., which has developed the underlying OPEP device platform and will serve as the manufacturing partner. The device features a patented three-resistance system designed to create pressure and vibrations during exhalation to help loosen mucus and open airways.

Speaking at the launch, Managing Director Sharvil Patel said PEPAIR™ is "India’s first affordable OPEP device," designed to support better breathing for patients with COPD, asthma and bronchiectasis.

OPEP-based airway clearance therapy is recommended in established clinical guidelines, but Zydus noted that limited affordability has restricted access for many patients in India — a gap the company aims to address with this launch.

Also read: GMR Airports shares gain 2% after Kotak upgrade; check target price

Zydus Life holds a portfolio spanning oral bronchodilators and inhalation therapies across single and combination drug categories. The company has introduced multiple therapies in the ICS+LABA, LABA+LAMA and triple-therapy segments in recent years.

India is experiencing a rise in respiratory diseases due to air pollution, climate-driven changes in allergens, rapid urbanisation and delayed diagnosis, creating a growing demand for accessible treatment solutions.

Zydus Lifesciences employs over 29,000 people globally, including around 1,500 scientists in research and development, and operates across multiple international markets.

Zydus Life's earnings performance for the December quarter beat street estimates, with the company's net profit rising 2% to ₹1,042 crore from ₹1,023.5 crore in the previous year. Revenue increased 30.3% to ₹6,865 crore from ₹5,269 crore in Q3FY25. It was also above the CNBC-TV18 poll's ₹6,294.3 crore.

The company's EBITDA increased 31% to ₹1,817 crore from ₹1,388 crore last year and was higher than market expectations of ₹1,516 crore. EBITDA margin expanded to 26.5% from 26.3% in the year-ago period and from the CNBC-TV18 poll's 24%.

Shares of the company were trdaing 0.19% up at ₹908.75 as of 11.28 am. The stock has gained 3.14% in the past month, but has lost 7.88% over the past six months.Continue Reading(Edited by : Anshul)Tagsair pollutionHealth and Climate changerespiratory diseasesshare market todayZydus Lifesciences